Overhauling Compliance and GMPs

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-04-02-2003, Volume 27, Issue 4

FDA's newly launched risk-based approach to GMP regulation spurs signficant changes in the agency's approach to inspection processes, postapproval changes, and 21 CFR Part 11 enforcement.

Related Content:

Regulatory/GMP ComplianceQuality SystemsRegulatory WatchPharmaceutical Technology-04-02-2003
Susan Schniepp of Regulatory Compliance Associates Explores the Impact of QMS on Quality Maturity (INTERPHEX 2024)
Keynote Session Highlights Importance of Process Validation and Data Integrity (INTERPHEX 2024)
FDA Establishes Center for Clinical Trial Innovation